Disc Medicine Shares Rise 60% After Phase 3 Bitopertin Trial Meets Primary and Secondary Endpoints
Disc Medicine (IRON) shares rose 60% after its Phase 3 APOLLO trial for bitopertin met primary and secondary endpoints. The trial showed a 41.4% reduction in protoporphyrin levels and increased pain-free light exposure. The company plans to resubmit an NDA by late 2026, with a potential FDA decision in mid-2027. Bitopertin was generally well-tolerated, with dizziness being the most common side effect.
How this was made
The 30-second read
Why it matters
The trial’s success may accelerate the NDA resubmission and drive further stock appreciation, but safety signals and FDA review risk remain.
Market read
First disclosure of pivotal Phase 3 data; material for investors in rare‑disease biotech.
What to watch
Regulatory timeline and reimbursement landscape remain uncertain.
Background
Disc Medicine (NASDAQ:IRON) focuses on treatments for erythropoietic protoporphyria, a rare inherited disorder.
Ticker impact
Shares jumped 60% after Disc Medicine reported its Phase 3 trial met all primary and secondary endpoints.
likely further upside as market prices in the FDA filing prospectus.
The trial results are a material catalyst; the stock already surged, but additional upside remains as the FDA review approaches.
Market effects
Boosts sentiment for rare‑disease biotech companies and may lift peer valuations.
Positive for US biotech sector.
Highlights progress in EPP treatment, potentially influencing global rare‑disease pipelines.
Counterpoint
Safety concerns (50% dizziness) could temper enthusiasm and delay FDA approval.
Key entities
- companyDisc Medicine, Inc.
Biotech firm developing bitopertin for EPP.
- regulatorFDA
U.S. agency that will review the NDA in mid‑2027.
